Old Web
English
Sign In
Acemap
>
Paper
>
Assessment of Plasma Proteomics Biomarker’s Ability to Distinguish Benign From Malignant Lung Nodules
Assessment of Plasma Proteomics Biomarker’s Ability to Distinguish Benign From Malignant Lung Nodules
2018
Gerard A. Silvestri
Nichole T. Tanner
Paul Kearney
Anil Vachani
Pierre P. Massion
Alexander Porter
Steven C. Springmeyer
Kenneth C. Fang
David Eric Midthun
Peter J. Mazzone
G.A. Silvestri
L. Leake
P. Mazzone
M. Beukemann
D. Midthun
P McCarthy
B. Sigal
T DeLuca
F. Laberge
B. Fortin
M. Balaan
B. Dimitt
A Pierre
F. Allison
L. Yarmus
K. Oakjones-Burgess
N. Tanner
N. Ettinger
T. Setchfield
D. Madtes
J. Hubbard
W. McConnell
K. Robinson
A. Lackey
L Jacques
E. Kuo
V. Markland-Gentles
P. Massion
A. Muterspaug
J Leach
K. Rothe
W Rom
H. Pass
A. Sorenson
A. Chesnutt
A. Georgeson
A. Balekian
J Fisher
R Murali
A. Overton
N Desai
A. Levesque
W. Krimsky
S King
A. Vachani
K. Maletteri
K. Mileham
L. Carter
G. Hong
J Ma
K. Voelker
H. Barrentine
R. Aronson
M. Henderson
J. Lamberti
C. Krawiecki
A Case
L. Wilkins
J.M. Ayers
K. Fangmann
J. Landis
L. DeSouza
Z. Hammoud
D. Kah
J. Sanchez
L Murdoch
Keywords:
Pathology
Intensive care medicine
Biomarker (medicine)
Proteomics
Medicine
Lung
Correction
Cite
Save
Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI
[]